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Summary: In case control and cohort studies in Malawi we found little evidence that non-
secretor/Lewis negative histo-blood group antigen phenotypes are associated with reduced 
rotavirus vaccine take in Malawian infants. Non-secretor phenotype was associated with reduced 
risk of clinical vaccine failure.  
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Abstract 
Background 
Histo-blood-group-antigen (HBGA) Lewis/secretor phenotypes are associated with susceptibility to 
genotype-specific rotavirus gastroenteritis (RVGE). We tested the hypothesis that non-
secretor/Lewis negative phenotype leads to reduced vaccine virus replication, IgA response and 
clinical protection following vaccination with G1P[8] rotavirus vaccine (RV1) in Malawian infants. 
Methods 
Infants receiving RV1 at age six and ten weeks were recruited to a cohort study. HBGA phenotype 
was determined by salivary ELISA. RV1 vaccine virus shedding was detected by qRT-PCR in stool 
collected on alternate days for ten days post-immunization. Plasma rotavirus (RV)-specific IgA was 
determined by ELISA pre-immunisation and following the second dose. In a case-control study, 
distribution of HBGA phenotype was compared between RV1-vaccinated infants hospitalized with 
RVGE and 1:1 age-matched community controls. Rotavirus genotype was determined by RT-PCR. 
Results 
In 202 cohort participants, neither overall vaccine virus faecal shedding nor seroconversion differed 
by secretor or Lewis phenotype. In 238 matched case-control infants, non-secretor phenotype was 
significantly less common in infants with clinical vaccine failure (OR 0.39, 95%CI 0.20-0.75). The 
prevalence of non-secretor phenotype was less common in infants with P[8] RVGE (OR 0.12, 95%CI 
0.03-0.50) and P[4] RVGE (OR 0.17, 95%CI 0.04-0.75). Lewis negative phenotype was more common 
in infants with P[6] RVGE (OR 3.2, 95%CI 1.4-7.2).  
 
Conclusions 
Non-secretor phenotype was associated with reduced risk of rotavirus vaccine failure. There was 
little evidence of a significant association between HBGA phenotype and vaccine take. These data 
refute the hypothesis that high prevalence of non-secretor/Lewis negative phenotypes contributes 
to lower rotavirus vaccine effectiveness in Malawi. 
Keywords: rotavirus, HBGA, vaccine, immunogenicity, Malawi 
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Background 
Introduction of rotavirus vaccines into childhood immunization programmes has reduced global child 
deaths from diarrhoeal disease [1], but current vaccines are less effective in low-income, high-
mortality countries than in higher income settings [2]. Multiple explanations for this disparity have 
been proposed, but definitive data are lacking [3]. A widely proposed hypothesis is that histo-blood 
group antigen (HBGA) phenotype could affect the replication of live rotavirus vaccines in the gut, 
potentially explaining observed population differences in rotavirus vaccine immunogenicity and 
effectiveness [4-9].  
HBGA are complex carbohydrates expressed on the surface of red blood cells and mucosal epithelial 
cells. Secretion of HBGA, as free oligosaccharides in saliva and other exocrine secretions, is 
determined by expression of the FUT2 gene. Mutations of FUT2 result in a non-functional enzyme 
and “non-secretor” phenotype. A combination of FUT2 and FUT3 gene expression determines the 
Lewis HBGA phenotype [10].  
Rotavirus is a double-stranded RNA virus comprising an eleven-segment genome in a triple-layer 
protein capsid.  Rotaviruses are classified by capsid protein G (glycoprotein VP7) and P (protease-
sensitive VP4) genotypes. HBGA glycans have been shown to bind in a strain-specific pattern to the 
VP8* sub-unit of VP4 [11-15]. In addition, epidemiological studies have shown that HBGA phenotype 
determines strain-specific susceptibility to RVGE. Secretor and Lewis positive phenotypes have been 
associated with increased risk of P[8] and P[4] rotavirus gastroenteritis (RVGE) [5, 7, 13, 16-20], and 
Lewis negative phenotype with increased risk of P[6] RVGE [5, 7].  
Both the monovalent human rotavirus vaccine Rotarix® (RV1) and pentavalent human-bovine 
reassortant vaccine Rotateq®, are based on attenuated P[8] strains. HBGA-associated resistance to 
P[8] vaccine virus replication could therefore diminish vaccine response. Evidence to support this 
hypothesis is limited and inconsistent and no data are available from sub-Saharan Africa [5, 6, 8]. 
Malawi is a low-income country which introduced RV1 nationally in 2012. Malawi has high rotavirus 
genotypic diversity, with around 20% of RVGE caused by P[6] strains [21].  Rotavirus vaccine 
effectiveness in the first year of life is estimated at 70% [22]. In this population, we sought to test 
the hypothesis that intrinsic resistance of Lewis negative/non-secretors to G1P[8] infection results in 
reduced IgA response, reduced vaccine virus replication and impaired clinical protection against 
severe rotavirus gastroenteritis following G1P[8] rotavirus vaccine. 
Methods 
The relationship between HBGA phenotype, vaccine virus replication and rotavirus-specific IgA 
response was determined in a longitudinal cohort study. The relationship between HBGA phenotype 
and clinical rotavirus vaccine failure was determined by a cross-sectional case-control study. Ethical 
approval for both studies was granted by the University of Malawi College of Medicine 
(P.09/14/1624) and University of Liverpool (00758) Research Ethics Committees.  
Study population 
Longitudinal cohort study 
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Healthy infants attending a vaccination clinic in Blantyre, Malawi were consecutively recruited,  from 
April 2015 to August 2016, prior to first RV1 immunization, following informed parental consent.  
Blood samples were taken prior to first RV1 dose (at approximately 6 weeks of age) and two weeks 
following the second RV1 dose (at approximately 12 weeks of age). Stool samples were taken on 
days 4, 6, 8 and 10 post immunization. 
 
Case control study 
Infants aged between 10 weeks and 1 year with severe gastroenteritis, defined as Vesikari score ≥11 
[23], were consecutively recruited, from January 2015 to January 2017, with informed parental 
consent, from a secondary referral hospital and three primary healthcare centres in Blantyre, 
Malawi. Stools were tested for rotavirus by rapid immunochromatography test (RotaStrip®, Coris 
Bioconcept, Belgium). Infants who tested rotavirus positive were recruited as rotavirus 
gastroenteritis cases (vaccine failures). Age-matched community controls without diarrhoea (for at 
least one week prior to recruitment), born within ±30 days of rotavirus gastroenteritis cases, were 
recruited from randomly generated locations within the healthcare catchment areas of each 
recruitment site in a 1:1 ratio. All cases and controls had received two doses of RV1 vaccine, 
confirmed by hand-held health records.  
Data collection and anthropometry 
Socio-economic and demographic data were collected by structured interview. Nutritional status 
was determined by measurement of length, weight and mid-upper arm circumference (MUAC, a 
measure of wasting) at time of recruitment, compared to WHO age-determined z scores [24]. 
Laboratory methods 
For detailed laboratory methods see Supplementary Methods. HBGA phenotyping was determined 
by detection of antigens A, B, H, and Lewis a and b in saliva by ELISA, using specific monoclonal 
antibodies, detected by peroxidase conjugated anti-mouse IgM. Infants with detectable salivary A, B 
or H antigen were classified as secretors. Where detection of A, B and H antigens was negative or 
borderline, secretor status was confirmed by ELISA to detect lectin antigen [25]. Infants who were 
positive for either Lewis a or Lewis b antigen were classed as Lewis positive, and those negative for 
both Lewis antigens as Lewis negative. FUT2 genotype was determined for infants of non-secretor 
phenotype with enough blood available. DNA was extracted from whole blood using the Qiagen DNA 
Blood Mini Kit (Qiagen, Germany), in accordance with manufacturer’s instructions. FUT2 was 
amplified by PCR and restriction fragment length polymorphism used to identify inactivating 
mutations.  
RV-specific IgA was determined by a custom antibody-sandwich ELISA [26]. Quantification was made 
by comparison to a standard plasma [27], reported as geometric mean concentration (GMC) in units 
per millilitre.  
Nucleic acid was extracted from stool using the Qiagen Viral RNA Mini-Kit (Qiagen, Germany). 
Reverse transcription using random primers was used to generate complementary DNA[28]. RV1 
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shedding was determined by vaccine-specific NSP2 real-time polymerase chain reaction (RT-PCR) 
[29] and confirmed by VP6 quantitative real-time polymerase chain reaction (qRT-PCR) [30] (S1), 
with a Ct cut-off value for positivity of <40 cycles. In case-control study participants, including 
community controls, rotavirus infection was defined as VP6 ≥100 copies/ml by qRT-PCR. In both 
cases and in asymptomatic rotavirus infections in controls, rotavirus genotyping was undertaken 
using two-stage RT-PCR [31].  
Statistical analysis 
All statistical analysis was performed in StataIC Version 13.1 (StataCorp, USA).  
Cohort Study 
RV1 vaccine virus shedding was defined as two or more NSP2 positive, VP6 positive samples post-
immunization. NSP2 positive, VP6 negative samples were considered negative. NSP2 negative, VP6 
positive samples were assumed to reflect wild-type infection. A minimum of two post-immunization 
samples were required for inclusion in shedding analysis.  Seropositivity was defined as RV-specific 
IgA >20U/mL. Seroconversion was defined as a change from seronegative pre-immunization to 
seropositive post-immunization, or at least a four-fold rise in RV-specific IgA concentration post-
immunization among infants seropositive at baseline. The relationship between HBGA phenotype 
(defined categorically on secretor and Lewis status) and these categorical outcomes was assessed by 
log-binomial regression. The relationship between HBGA phenotype and continuous variables (peak 
vaccine virus shedding, RV-specific IgA geometric mean concentration) was determined by Wilcoxon 
rank-sum test.  
For the cohort study, a sample size of 200 was estimated to achieve 80% power to detect a risk ratio 
of 0.5 (versus equal risk, alpha 0.05).  
Case-control study 
The odds of specific HBGA phenotype (defined categorically on secretor and Lewis status) was 
compared between cases and matched community controls by conditional logistic regression. With 
1:1 controls, a sample size of 123 cases was estimated to achieve 80% power to detect an odds ratio 
of 2.5 (versus equal odds, alpha 0.05). 
Genotyping analysis 
In an additional case-control analysis, the distribution of HBGA phenotype by genotype-specific 
rotavirus gastroenteritis was compared to community controls. This stratified analysis was 
unmatched, as there were too few matched pairs for meaningful analysis. Separate analyses 
determined distribution of HBGA phenotype in P[8], P[4] and P[6] rotavirus gastroenteritis compared 
to community controls by logistic regression. Rotavirus cases where genotype could not be 
confirmed were excluded.  
A descriptive analysis of HBGA phenotype distribution in genotype-specific asymptomatic rotavirus 
infection in community controls was made.  
Results 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciy1067/5252030 by guest on 21 D
ecem
ber 2018
 7 
 
COHORT STUDY 
HBGA phenotype, RV1 faecal shedding and seroconversion 
Two-hundred and ninety-three infants were recruited to the cohort study. Of these, 243 infants in 
the first dose period, 214 infants in the second dose period, and 202 infants in both dose periods, 
provided at least two stool samples. Both pre- and post-immunisation samples for RV-specific IgA 
were provided by 196 infants. Demographic characteristics were similar in those with complete data 
compared to those with incomplete data (Supplementary Tables 1-2).  
Compared to secretor infants, non-secretors had significantly reduced risk of vaccine virus faecal 
shedding in the first dose period, but not in the second. The overall risk of vaccine virus faecal 
shedding, in infants with data for both dose periods, did not differ between non-secretors and 
secretors (Table 1). 
In a stratified analysis comparing shedding by sampling day, non-secretors had significantly reduced 
risk of vaccine virus shedding (4/49, 8%) compared to secretors (51/182, 28%) on day 10 following 
the first vaccine dose. Risk of vaccine virus shedding was not significantly different between non-
secretors and secretors on other sampling days in the first dose period, or on any day in the second 
dose period (Supplementary Table 3). There was no difference in peak level of vaccine virus 
shedding, as determined by NSP2 cycle threshold (Ct) value by secretor status(Table 1). When Ct 
values were compared by sample day, median Ct values in non-secretors were higher (viral load 
lower) compared to secretors on days 6 and 8 following the first vaccine dose, but not on any other 
sample day (Supplementary Table 4).  
There was no difference in vaccine virus faecal shedding between Lewis negative and Lewis positive 
infants by any categorical or quantitative measure (Table 2, Supplementary Tables 3-4).  
Paired serological data were available for 196 cohort infants. Of these infants, 47 (24%) 
seroconverted. Eleven (6%) infants were seropositive at baseline. The risk of seroconversion was 
similar in baseline seropositive infants compared to baseline seronegative infants (RR 0.75 (95%CI 
0.21-2.7, p=0.66). The risk of seroconversion did not differ by secretor or Lewis phenotype (Tables 1 
and 2). 
Among infants with detectable post-immunization RV-specific IgA, there was no difference in GMC 
between secretors and non-secretors, or between Lewis positive and negative infants (Tables 1 and 
2). 
In a sensitivity analysis where secretor/non-secretor status was re-categorised by confirmatory FUT2 
genotyping and phenotype at 10 weeks old, there remained no association between non-secretor 
status and either vaccine virus shedding or seroconversion (Supplementary Table 5). Concordance 
between genotype and phenotype was 90%.  
There was no difference in vaccine virus shedding or seroconversion when secretor phenotype was 
stratified by Lewis phenotype (Supplementary Table 6). In a sub-analysis of secretor infants, there 
was no association between ABO phenotype and either vaccine virus shedding or seroconversion 
(Supplementary Tables 7-8).  
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CASE CONTROL STUDY 
One hundred and nineteen eligible severe rotavirus gastroenteritis cases and 119 age-matched 
community controls were recruited. Median MUAC was lower in RVGE cases (13.1cm (IQR 12.4-
14cm)) than in community controls (13.8cm (IQR 13.2-14.5cm), p<0.01). No other differences in 
anthropometric or socio-economic characteristics between cases and controls were observed 
(Supplementary Table 9).  
HBGA phenotype distribution in infants with RV1 clinical vaccine failure 
The prevalence of non-secretor phenotype was significantly lower in infants with clinical RV1 vaccine 
failure (14/119, 12%), compared to community controls (33/119, 28%). The odds of non-secretor 
phenotype were over 60% lower in RV1 vaccine failures than in age-matched community controls 
(Table 3).  In a sensitivity analysis where secretor/non-secretor status was re-categorised by FUT2 
genotyping, the distribution of non-secretor phenotype in RV1 vaccine failures and controls was 
unchanged (OR 0.36, 95%CI 0.17-0.74) (Supplementary Table 10).  Concordance between genotype 
and phenotype was 86%.  
There was no association between Lewis phenotype and RV1 vaccine failure (Table 3). 
There was no change in observed associations when secretor phenotype was stratified by Lewis 
phenotype (Supplementary Table 11). In a sub-analysis of secretor infants, there was no association 
between ABO phenotype and RV1 vaccine failure (Supplementary Tables 12-13).  
HBGA phenotype and genotype-specific susceptibility to rotavirus GE 
Rotavirus G or P type was confirmed in 116/119 rotavirus gastroenteritis cases. Median virus load in 
genotyped rotavirus cases was 1.4x107 (IQR 1.5 x106-4.8x107) copies/ml. P-type was confirmed in 
114/119 rotavirus gastroenteritis cases.  
Genotype distribution of RVGE cases is shown in Figure 1A. The four most common genotypes 
accounted for over 75% of genotyped rotavirus gastroenteritis cases: G1P[8] (32%), G2P[4] (26%), 
G12P[6] (10%) and G2P[6](9%).  
The prevalence of non-secretor phenotype was significantly lower in infants with P[8] RVGE (2/47, 
4%) and P[4] RVGE (2/38, 5%) compared to community controls (33/119, 28%) (Table 4). All 44 
infants with G1P[8] gastroenteritis were secretors. The prevalence of non-secretor phenotype 
between infants with P[6] RVGE and community controls did not differ (Table 4).  
Similarly, the prevalence of Lewis negative phenotype was lower in infants with P[8] RVGE (4/47, 9%) 
and P[4] RVGE (2/38, 5%) than in community controls (31/119, 26%) (Table 4). In contrast, the 
prevalence of Lewis negative phenotype was higher in infants with P[6] RVGE (13/33, 39%) than in 
community controls (Table 4).  The odds of infants being Lewis negative were increased over three-
fold in those with P[6] RVGE (Table 4) compared to community controls.  
HBGA phenotype and asymptomatic rotavirus infection 
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Asymptomatic rotavirus infection was common: 52/119 (54%) of community controls had detectable 
rotavirus above 100 copies/ml, with a median viral load of 628 (IQR 258-2008) copies/ml. Due to low 
viral load, full genotype was only available in 21 asymptomatic infections, and partial genotype in a 
further 7 (Figure 1B).  
The distribution of HBGA phenotypes in genotype-specific asymptomatic infection were similar to 
those in the wider community control population: 5/16 (31%) infants with P[8] asymptomatic 
infections and 3/11 (27%) infants with P[4] asymptomatic infection were non-secretors. Three of 
eight (38%) infants with G1P[8] asymptomatic infection were non-secretors.  
Discussion 
Contrary to our initial hypothesis, non-secretor phenotype was significantly less prevalent in infants 
with clinical vaccine failure. We found limited evidence that non-secretor phenotype was associated 
with reduced vaccine take. The proportion of infants with RV1 vaccine virus shedding in the first 
dose period was lower in non-secretors compared to secretors, with lower quantitative shedding on 
some sample days, but the overall risk of vaccine virus shedding, and peak shedding level did not 
differ. The proportion of infants with post-immunization RV-specific IgA seroconversion was lower in 
non-secretors compared to secretors but not significantly so. Non-secretor phenotype was 
associated with protection against both P[8] and P[4] rotavirus gastroenteritis, the two most 
common rotavirus strains in Malawi. Similarly, against our initial hypothesis, there was no observed 
association between Lewis negative phenotype and either rotavirus vaccine take or clinical vaccine 
failure. Lewis negative phenotype was less common in infants with P[8] and P[4] gastroenteritis, but 
more common in infants with P[6] gastroenteritis, the third most common strain in this study 
population. These opposing effects may have brought the association between Lewis phenotype and 
rotavirus vaccine failure toward the null.  
The lower point estimate of seroconversion in non-secretor infants (13% compared to 27% in 
secretor infants) is consistent with previous studies. Bucardo et al. (2018) [6] in Nicaragua reported 
similar findings, while Kazi et al. (2017) [8] in Pakistan reported lower seropositivity following 3 
doses of RV1 in non-secretors. Our finding that non-secretor infants are relatively protected from 
rotavirus gastroenteritis is consistent with data from Bangladesh where non-secretor phenotype was 
associated with a decreased risk of rotavirus diarrhoea in unvaccinated infants [5]. This study did not 
demonstrate a significant association between non-secretor phenotype and risk of rotavirus vaccine 
failure, but numbers of vaccine failures were small. Our findings are also consistent with surveillance 
data from the US, where non-secretors were at greatly reduced risk of vaccine failure [19], although 
notably in this population 91% of gastroenteritis cases were due to P[8] infection.  
Non-secretor phenotype distribution was similar in infants with asymptomatic rotavirus infection 
compared to the general study population. This could suggest that non-secretor phenotype provides 
relative protection against rotavirus disease, but not against asymptomatic infection. This “partial 
resistance” might explain the limited effect of non-secretor phenotype on vaccine virus shedding. 
Asymptomatic infection could potentially allow further boosting of protective immunity [32]. Our 
study is the first to report on the relationship between HBGA phenotype and asymptomatic rotavirus 
infection. Although the number of infants with asymptomatic infection was high, as observed in 
other low-income settings[26, 33, 34], the number of genotyped asymptomatic infections was small 
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and conclusions should be considered within this context. However our findings are consistent with 
data from Lee et al (2018) in Bangladesh, in a prospective cohort including mild diarrhoea, where 
P[8] infection was not associated with secretor phenotype [5]. Most prior studies on the relationship 
between HBGA phenotype and rotavirus have focused on hospitalized RVGE. Further data on mild 
and asymptomatic infections are required to confirm this partial resistance hypothesis.  
Our study has several limitations. The lower than expected seroconversion rate may have limited 
analytic power. Exposure to wild-type rotavirus may have increased post-immunisation 
seropositivity. However, since non-secretors are protected against wild-type infection, any bias 
would be toward reduced post-immunisation RV-specific IgA in this group. Subtle differences in 
vaccine virus shedding may have been underestimated by semi-quantitative measures (Ct value) and 
borderline results might be clearer in a larger population. Our study relied primarily on salivary 
HBGA phenotyping by ELISA, which may be less sensitive than genotyping, although concordance 
between genotyping and phenotyping was high. Furthermore, sensitivity analysis using FUT2 
genotyping strengthened the observed protective association between non-secretor type and odds 
of clinical vaccine failure.  
In summary, we found little evidence in this population that non-secretor phenotype was 
significantly associated with reduced vaccine take. Any possible phenotypic disadvantage in vaccine 
response was clearly outweighed  by non-secretors’ relative resistance to wild-type P[8] and P[4] 
infections, even in this population in which  P[6] RVGE was common (>20%). A similar balance would 
likely exist in other countries with a similar or lower proportion of P[6] RVGE.  Recent data show 
other sub-Saharan African countries have a similar prevalence of P[6] RVGE to Malawi, while the 
prevalence in all other world regions is substantially lower [35, 36]. While the prevalence of P[6] 
could vary over time, we contend that HBGA phenotype is highly unlikely to contribute to current 
population differences in rotavirus vaccine effectiveness between high and low income countries.  
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Table 1: Vaccine virus shedding and RV-specific IgA response by secretor phenotype 
 Secretor Non-secretor RR (95%CI) p value 
Vaccine virus shedding  
1st dose period n, % (95%CI) 
63/188, 34 
(27-41%) 
10/55, 18 
(10-31%) 
0.54 
(0.3-0.98) 
0.04 
Vaccine virus shedding 
2nd dose period n, % (95%CI) 
58/169, 34 
(27-42%) 
12/45, 27 
(15-42%) 
0.78 
(0.5-1.3) 
0.35 
Overall vaccine virus shedding n, % 
(95%CI) 
86/157, 55 (47-
62%) 
18/45, 40 
(26-55%) 
0.73  
(0.5-1.1) 
0.11a 
Peak vaccine virus sheddingb  
1st dose period Median Ct (IQR) 
29.3  
(25.9-32.3) 
31.9  
(30.4-34.1) 
 0.13c 
Peak vaccine virus sheddingb 
 2nd dose period Median Ct (IQR) 
32.4  
(30.6-34.7) 
34.1  
(31.9-35.0) 
 0.21c 
Seroconversion 
n, % (95%CI) 
41/151, 27 (21-
35%) 
6/45, 13  
(6-27%) 
0.50 
(0.2-1.1) 
0.08a 
Post-immunization  
RV-specific IgAd GMC (95% CI) 
109.3  
(78.7-151.8) 
81.3  
(47.9-137.9) 
 0.52c 
n=number, %=percent, RR=risk ratio of vaccine virus faecal shedding/seroconversion in non-secretor 
infants compared to secretor infants. Ct=cycle threshold IQR =inter-quartile range, GMC= geometric 
mean concentration. a. log-binomial regression b. Peak vaccine virus shedding based on minimum 
NSP2 RT-PCR Ct value detected within dose period. c. Wilcoxon rank-sum test. d. Only infants with 
detectable post-immunization RV-specific IgA >20U/ml were included for analysis. This included 
24/151(30%, 95%CI 23-38%) secretor and 9/45 (20%, 95%CI 10-35%) non-secretor infants.  
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Table 2: Vaccine virus shedding and RV-specific IgA response by Lewis phenotype 
 Lewis positive Lewis negative RR 
(95%CI) 
p value 
Vaccine virus shedding  
1st dose period n, % (95%CI) 
59/193, 31 
(24-37%) 
14/50, 28 
(17-42%) 
0.92 
(0.56-1.5) 
0.73 
Vaccine virus shedding 
2nd dose period n, % (95%CI) 
57/169, 34 
(27-41%) 
13/45, 29 
(17-44%) 
0.86 
(0.52-1.4) 
0.55 
Overall vaccine virus shedding 
n, %, RR (95%CI) 
84/159, 53 
(45-61%) 
20/43, 47  
(32-62%) 
0.88  
(0.6-1.3) 
0.48a 
Peak vaccine virus sheddingb 1st 
dose period Median Ct (IQR) 
29.8  
(26.4-32.4) 
31.2  
(28.0-34.0) 
 0.41c 
Peak vaccine virus sheddingb 2nd 
dose period Median Ct (IQR) 
32.1 
(30.6-34.7) 
33.9 
(32.7-35.4) 
 0.15 c 
Seroconversion 
n, %, RR (95%CI) 
35/149, 24 
(17-31%) 
12/47, 26  
(15-40%) 
1.1  
(0.6-1.9) 
0.77 a 
Post-immunization  
RV-specific IgAd GMC (95% CI) 
114.5 
(84.7-154.9) 
74.5 
(35.2-157.6) 
 0.17 c 
n=number, %=percent, RR=risk ratio of vaccine virus faecal shedding/seroconversion in Lewis 
negative infants compared to Lewis positive infants. Ct=cycle threshold IQR =inter-quartile range, 
GMC= geometric mean concentration. a. log-binomial regression b. Peak vaccine virus shedding 
based on minimum NSP2 RT-PCR Ct value detected within dose period. c. Wilcoxon rank-sum test. d. 
Only infants with detectable post-immunization RV-specific IgA >20U/ml were included for analysis. 
This included 42/149(28%, 95%CI 21-36%) Lewis positive and 12/47(26%, 95%CI 15-40%) Lewis 
negative infants.  
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Table 3:HBGA phenotype distribution in rotavirus vaccine failures and community controls 
HBGA phenotype Prevalence in  
RV GE cases (Vaccine 
failures) 
n, % (95%CI) 
Prevalence in 
Community Controls 
n, % (95%CI) 
Odds ratioa (95%CI) 
p value 
Non-secretor 14/119 
12 (7-19%) 
33/119 
28 (20-37%) 
0.39 (0.20-0.75) 
p=0.005 
Lewis negative 24/119 
20 (14-28%) 
31/119 
26 (19-35%) 
0.70 (0.37-1.3) 
p=0.27 
n=number, %=percent a. Odds ratio of non-secretor/Lewis negative phenotype in vaccine failures 
compared to age-matched controls, p value determined by conditional logistic regression.  
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Table 4: HBGA phenotype distribution in genotype-specific RVGE 
HBGA 
phenotype 
Community 
Controls 
n, % 
P[8] RVGE  
n, % 
ORa (95%CI) 
p value 
P[4] RVGE 
n, %  
OR (95%CI) 
p value 
P[6] RVGE 
n, %  
OR (95%CI) 
p value 
Non-secretor 
 
33/119, 28 
 
2/47, 4 
0.12 (0.03-0.50) 
0.004 
2/38, 5 
0.17 (0.04-0.75) 
0.02 
7/33, 21 
1.1 (0.42-2.7) 
0.90 
Lewis 
negative 
 
31/119, 26 4/47, 9 
0.26 (0.09-0.80) 
0.02 
2/38, 5 
0.17 (0.04-0.73) 
0.02 
13/33, 39 
3.2 (1.4-7.2) 
0.006 
n=number, %=percent a. Odds ratio of non-secretor/Lewis negative phenotype in genotype-specific 
RVGE cases compared to community controls, p value determined by logistic regression.  
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Figure 1: Common genotypes in RV GE cases and asymptomatic infection 
A: Common genotypes in RV GE cases B: Common genotypes in asymptomatic RV infection. Partial 
genotypes – P or G type only confirmed. Mixed infection – more than one G or P type identified. 
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